Recherche: Survodutide

Dual GLP-1/glucagon agonist in development

Survodutide Research Papers & Clinical Studies

Survodutide is a peptide studied for its potential therapeutic effects. Dual GLP-1/glucagon agonist in development This page indexes all published research papers, clinical trials, and scientific studies related to Survodutide that are available in the PepsReview research library. Each paper includes metadata such as journal name, publication year, citation count, study type, and a summary of key findings. Where available, we provide direct links to the original publication and DOI references.

Researchers can use this index to quickly locate evidence supporting specific Survodutide applications, compare study designs, and evaluate the strength of clinical evidence. Papers are sorted by relevance and citation count. There are currently 5 research papers indexed for Survodutide.

For vendor pricing, user reviews, and a complete peptide profile including mechanism of action, benefits, side effects, and regulatory status, visit the main Survodutide profile page.

Survodutide
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Lancet Diabetes Endocrinol 2024 300 Clinical Trial
Phase 2 trial: survodutide (GLP-1/glucagon dual agonist) demonstrated significant weight loss across dose levels in adults with obesity across 12 countries.
Survodutide Once Weekly for the Treatment of Adults with Obesity
N Engl J Med 2026 200 Research Article
Phase 3 trial of once-weekly survodutide (GLP-1/glucagon dual agonist) for obesity treatment in adults, building on promising Phase 2 weight loss results.
Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial
JACC Heart Fail 2024 40 Clinical Trial
SYNCHRONIZE-CVOT: Phase 3 cardiovascular safety trial of survodutide (dual GLP-1/glucagon agonist) assessing CV outcomes in adults with obesity and CVD risk.
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1)
Diabetes Obes Metab 2026 10 Clinical Trial
SYNCHRONIZE-1 Phase 3 trial reporting baseline characteristics of participants receiving survodutide (GLP-1/glucagon dual agonist) for obesity management without T2D.
Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes
Diabetes Obes Metab 2026 10 Clinical Trial
SYNCHRONIZE-2 Phase 3 trial: baseline characteristics of adults with obesity and type 2 diabetes receiving survodutide (GLP-1/glucagon dual agonist).